Latest news with #Alkem
Mint
3 days ago
- Business
- Mint
Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza *
Mint
3 days ago
- Business
- Mint
Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza * Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Alkem Labs Q1 profit rises 22% to ₹664 cr on India, overseas sales growth
Alkem Laboratories on Tuesday reported a 22 per cent year-on-year (Y-o-Y) rise in its consolidated net profit for the June quarter (Q1FY26) to ₹664.3 crore, up from ₹545.2 crore in the same period last year. Revenue from operations increased 11.2 per cent Y-o-Y to ₹3,371 crore in Q1FY26 from ₹3,031 crore in Q1FY25. The company attributed this growth to strong sales in both India and international markets. Commenting on the performance, Vikas Gupta, Chief Executive Officer of Alkem, said Q1FY26 marked a strong start to the year, with healthy growth across both domestic and overseas markets. India sales grew 12 per cent Y-o-Y to ₹2,265 crore in the June quarter, while international sales rose 8.9 per cent to ₹1,054 crore, contributing 31.7 per cent to overall revenue. In the international business, the United States market recorded sales of ₹698 crore, up 8.8 per cent from ₹641.6 crore a year earlier, contributing 21 per cent to total sales. Sales from other international markets — including Latin America, Australia, and Europe — rose 9.1 per cent to ₹355.6 crore, contributing 10.7 per cent to revenue. Gupta said the company is strategically accelerating its focus on the non-US business segment by strengthening its presence in high-potential markets and capturing new opportunities aligned with Alkem's long-term growth ambitions. Alkem also announced it will incorporate a Saudi Arabia-based subsidiary, holding a 51 per cent stake. 'The subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing, and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia,' the company said in a filing to the exchanges. On Tuesday, Alkem Laboratories' share price rose 6.7 per cent to close at ₹5,167 on the Bombay Stock Exchange (BSE).
Business Upturn
4 days ago
- Business
- Business Upturn
Alkem Laboratories shares jump 6% on strong Q1 results
Alkem Laboratories' stock jumped over 6% after the pharma major delivered an impressive set of numbers for the quarter ended June 30, 2025, driven by robust domestic and international performance. As of 1:46 PM, the shares were trading 6.04% higher at Rs 5,137.00. The company's consolidated net profit rose 21.45% year-on-year to ₹668 crore, compared to ₹550 crore in the same period last year. Revenue climbed 11.2% to ₹3,371 crore from ₹3,031.8 crore, while EBITDA grew 21.35% to ₹739 crore, up from ₹609 crore a year ago. Margins also improved to 21.9%, against 20% in the previous year, reflecting operational efficiency. Domestic market The domestic formulations business remained Alkem's biggest revenue contributor, generating ₹2,265 crore in sales — a 12% YoY increase and accounting for 68.3% of the company's total revenue. As per IQVIA (SSA) data, Alkem outperformed the Indian Pharmaceutical Market (IPM) in seven key therapies — Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology — growing at 1.1x to 2.3x the market rate. International market International sales rose 8.9% YoY to ₹1,053.9 crore. The US business, which contributes 21% to total sales, clocked ₹698.2 crore, up 8.8% from last year. Non-US international markets brought in ₹355.6 crore, marking a 9.1% increase and contributing 10.7% to total revenue. In the US market, Alkem made significant strides, including filing its first Biologics License Application (BLA), securing five Abbreviated New Drug Application (ANDA) approvals (two tentative), and launching three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two New Drug Applications (NDAs), and one BLA with the USFDA, with approvals for 160 ANDAs (including 15 tentative) and both NDAs. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash
&w=3840&q=100)
Business Standard
13-06-2025
- Business
- Business Standard
IPO-bound Allchem in legal tussle with Alkem over trademark infringement
IPO-bound Allchem Lifesciences adds legal dispute with Alkem to DRHP as Delhi HC directs both firms to mediation and next hearing is scheduled for 9 July Sanket Koul New Delhi Listen to This Article Vadodara-based Allchem Lifesciences on Friday issued an addendum to its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (Sebi), highlighting a suit filed by Alkem Laboratories against it in the Delhi High Court. The suit, filed on 23 April, alleges infringement of Alkem Labs' trademark with respect to the use of the name Allchem by the initial public offering (IPO)-bound company. In its submission to the Delhi HC, Alkem has sought a permanent injunction on the use of the name 'Allchem' and the offer under this name, along with damages of ₹2 crore for the
